Rodrigo Martinez Maza

Dr. Rodrigo Martinez Maza

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1997 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JSJon Schoorlemmer
Jon Schoorlemmer
CMCamelia Marcos‐Gutiérrez
Camelia Marcos‐Gutiérrez
FWFelipe Were
Felipe Were
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
EGEmiliano García
Emiliano García
MVMiguel Vidal
Miguel Vidal
In Drosophila , the products of the Polycomb group ( Pc‐G ) of genes act as chromatin‐associated multimeric protein complexes that repress expression of homeotic genes. Vertebrate Pc‐G homologues have been identified, but the nature of the complexes they form and the mechanisms of their action are largely unknown. The Polycomb homologue M33 is implicated in mesoderm patterning in the mouse and here we show that it acts as a transcriptional repressor in transiently transfected cells. Furthermore, we have identified two murine proteins, Ring1A and Ring1B, that interact directly with the repressor domain of M33. Ring1A and Ring1B display blocks of similarity throughout their sequences, including an N‐terminal RING finger domain. However, the interaction with M33 occurs through a region at the C‐terminus. Ring1A represses transcription through sequences not involved in M33 binding. Ring1A protein co‐localizes in nuclear domains with M33 and other Pc‐G homologues, such as Bmi1. The expression of Ring1A at early stages of development is restricted to the neural tube, whereas M33 is expressed ubiquitously. Within the neural tube, Ring1A RNA is located at the rhombomere boundaries of the hindbrain. Taken together, these data suggest that Ring1A may contribute to a tissue‐specific function of Pc‐G–protein complexes during mammalian development.

1 January 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
MNManuel Nieto-Diaz
Manuel Nieto-Diaz
Francisco J. EstebanFrancisco J. Esteban
Francisco J. Esteban
DRDavid Reigada
David Reigada
TMTeresa Muñoz-Galdeano
Teresa Muñoz-Galdeano
MYMónica Yunta
Mónica Yunta
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
Trauma to the spinal cord causes permanent disability to more than 180,000 people every year worldwide. The initial mechanical damage triggers a complex set of secondary events involving the neural, vascular, and immune systems that largely determine the functional outcome of the spinal cord injury (SCI). Cellular and biochemical mechanisms responsible for this secondary injury largely depend on activation and inactivation of specific gene programs. Recent studies indicate that microRNAs function as gene expression switches in key processes of the SCI. Microarray data from rodent contusion models reveal that SCI induces changes in the global microRNA expression patterns. Variations in microRNA abundance largely result from alterations in the expression of the cells at the damaged spinal cord. However, microRNA expression levels after SCI are also influenced by the infiltration of immune cells to the injury site and the death and migration of specific neural cells after injury. Evidences on the role of microRNAs in the SCI pathophysiology have come from different sources. Bioinformatic analysis of microarray data has been used to identify specific variations in microRNA expression underlying transcriptional changes in target genes, which are involved in key processes in the SCI. Direct evidences on the role of microRNAs in SCI are scarcer, although recent studies have identified several microRNAs (miR-21, miR/486, miR-20) involved in key mechanisms of the SCI such as cell death or astrogliosis, among others. From a clinical perspective, different evidences make clear that microRNAs can be potent therapeutic tools to manipulate cell state and molecular processes in order to enhance functional recovery. The present article reviews the actual knowledge on how injury affects microRNA expression and the meaning of these changes in the SCI pathophysiology, to finally explore the clinical potential of microRNAs in the SCI.

12 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMónica Yunta
Mónica Yunta
MNManuel Nieto-Díaz
Manuel Nieto-Díaz
Francisco J. EstebanFrancisco J. Esteban
Francisco J. Esteban
MCMarcos Caballero-López
Marcos Caballero-López
RNRosa Navarro-Ruíz
Rosa Navarro-Ruíz
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
Spinal cord injury (SCI) triggers a multitude of pathophysiological events that are tightly regulated by the expression levels of specific genes. Recent studies suggest that changes in gene expression following neural injury can result from the dysregulation of microRNAs, short non-coding RNA molecules that repress the translation of target mRNA. To understand the mechanisms underlying gene alterations following SCI, we analyzed the microRNA expression patterns at different time points following rat spinal cord injury. The microarray data reveal the induction of a specific microRNA expression pattern following moderate contusive SCI that is characterized by a marked increase in the number of down-regulated microRNAs, especially at 7 days after injury. MicroRNA downregulation is paralleled by mRNA upregulation, strongly suggesting that microRNAs regulate transcriptional changes following injury. Bioinformatic analyses indicate that changes in microRNA expression affect key processes in SCI physiopathology, including inflammation and apoptosis. MicroRNA expression changes appear to be influenced by an invasion of immune cells at the injury area and, more importantly, by changes in microRNA expression specific to spinal cord cells. Comparisons with previous data suggest that although microRNA expression patterns in the spinal cord are broadly similar among vertebrates, the results of studies assessing SCI are much less congruent and may depend on injury severity. The results of the present study demonstrate that moderate spinal cord injury induces an extended microRNA downregulation paralleled by an increase in mRNA expression that affects key processes in the pathophysiology of this injury.

13 November 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
BLBeatriz López-Corcuera
Beatriz López-Corcuera
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
ENEnrique Núñez
Enrique Núñez
MRMichel J Roux
Michel J Roux
SSStéphane Supplisson
Stéphane Supplisson
CACarmen Aragón
Carmen Aragón
Clonal cell lines stably expressing the glial glycine transporter 1b (GLYT1b) and the neuronal glycine transporter 2 (GLYT2) from rat brain have been generated and used comparatively to examine their kinetics, ion dependence, and electrical properties. Differential sensitivity of the transporters to sarcosine is clearly exhibited by the clonal cell lines. GLYT2 transports glycine with higher apparent affinity than GLYT1b and is not inhibited by any assayed compound, as deduced by glycine transport assays and electrophysiological recordings. A sigmoidal Na+ dependence of the glycine uptake by the stable cell lines is observed, indicating the involvement of more than one Na+ in the transport process. A more cooperative behavior for Na+ of GLYT2 than GLYT1b is suggested. One Cl− is required for GLYT1b and GLYT2 transport cycles, although GLYT1b shows three times higher affinity for this ion than GLYT2. The number of expressed transporters was sufficient to allow electrophysiological recordings of the uptake current in the two stable cell lines. GLYT2 exhibits more voltage dependence in both its glycine‐evoked current and its capacitive currents recorded in the absence of substrate.

1 June 2003 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
TTThorsten Trapp
Thorsten Trapp
LKLaura Korhonen
Laura Korhonen
MBMichael Besselmann
Michael Besselmann
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
EMEric A Mercer
Eric A Mercer
DLDan Lindholm
Dan Lindholm

2 November 2019 in Biotechnology Journal
Verified
Journal Article
Open access
PDF file
SGSantiago Grijalvo
Santiago Grijalvo
MNManuel Nieto-Diaz
Manuel Nieto-Diaz
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
Ramon EritjaRamon Eritja
Ramon Eritja
DDDavid Diaz
David Diaz
Alginate (ALG) is a lineal hydrophilic polysaccharide present in brown algae cell walls, which turns into a gel state when hydrated. Gelation readily produces a series of three dimensional (3D) architectures like fibers, capillaries, and microspheres, used as biosensors and bio‐actuators in a plethora of biomedical applications like drug delivery and wound healing. Hydrogels have made a great impact on regenerative medicine and tissue engineering because they are able to mimic the mechanical properties of natural tissues due to their high water content. Recent advances in neurosciences have led to promising strategies for repairing and/or regenerating the damaged nervous system. Spinal cord injury (SCI) is particularly challenging, owing to its devastating medical, human, and social consequences. Although effective therapies to repair the damaged spinal cord (SC) are still lacking, multiple pharmacological, genetic, and cell‐based therapies are currently under study. In this framework, ALG hydrogels constitute a source of potential tools for the development of implants capable of promoting axonal growth and/or delivering cells or drugs at specific damaged sites, which may result in therapeutic strategies for SCI. In this mini‐review, the current state of the art of ALG applications in neural tissues for repairing the damaged spinal cord is discussed.